More Access and Evidence Articles

Access and Evidence

Going Through the Motions

Adam Chapman, (Aug 6, 2018)

Both pharma and payers say they need to talk more, but are they really listening?
Access and Evidence

Navigating the Chaos

Adam Chapman, (Aug 6, 2018)

With the access landscape shifting rapidly, pharma needs to watch its step
Access and Evidence

Seeking the Holy Grail of RWE

Adam Chapman, (Aug 2, 2018)

Universal standards for real-world evidence are closer than you might think
Access and Evidence

United: How employers are changing healthcare

Hugh Gosling, (Jul 27, 2018)

The growth in employer coalitions are a sign that plan sponsors are increasingly flexing their muscles, but what do they hope to achieve?
Access and Evidence

Writing the Value Story

Adam Chapman, (Jul 19, 2018)

When writing the value story for a new medicine, starting earlier in Development will make sure it’s a page-turner
Access and Evidence

Pragmatic Trials: RWE’s Hidden Gem

Ross Davies, (Jun 20, 2018)

Pragmatic trials continue to be overlooked in the RWE space – particularly in the US. Can we expect to see wider stateside adoption?
Access and Evidence

The Naked Truth About Outcomes-Based Pricing

Ross Davies, (May 22, 2018)

Hype around outcomes-based contracts has been doing the rounds for some time now, but is pharma delivering the goods?
Access and Evidence

Japan’s Perilous New Pricing Policy

Ross Davies, (Apr 13, 2018)

The introduction of a new drug pricing reform in Japan has pharma up in arms. Are their fears justified?
Access and Evidence

Digital Health Tools Are No Fad

Adam Chapman, (Mar 14, 2018)

Data generating devices may seem gimmicky, but they are poised to transform healthcare
Access and Evidence

Overcoming The Access Hurdle

Adam Chapman, (Mar 6, 2018)

If pharma is to keep whizzing ahead, it needs to rethink its approach to market access